North America Smart Inhalers Market

North America Smart Inhalers Market Size (2023 to 2028)

The size of the North American smart inhalers market was worth USD 35.90 million in 2023 and is estimated to be growing at a CAGR of 67.54% to reach USD 473.95 million by 2028. 

The growing prevalence of respiratory disorders in North America primarily fuels the growth of the smart inhaler market in North America. Approximately 5.6% of adults in the United States were afflicted by chronic obstructive pulmonary disease (COPD) in 2020. Factors such as heightened smoking rates, exposure to smoke from various sources, genetic predisposition to asthma, and vulnerable lung conditions contribute to COPD incidence. To address these concerns, healthcare providers recommend the utilization of smart inhalers to manage respiratory challenges effectively.

The growing geriatric demographic and increasing awareness of smart inhalers promote the growth of North American market. Asthma remains prevalent among adults aged 64 and above, affecting approximately 8% of the older U.S. population. Educational initiatives have been undertaken to impart proficient handling and optimal use of smart inhalers, mitigating potential complexities. Inhalers are vital in treating chronic obstructive pulmonary diseases, notably asthma. Distinguished by their electronic monitoring capacity, smart inhalers facilitate controlled medication delivery directly to the airway, bypassing systemic circulation. Notably, these devices incorporate Bluetooth-enabled connectivity with mobile applications, ensuring precise administration and data collection, encompassing usage time, date, location, and even reminders for subsequent doses.

Continuous advancements in the manufacturing of smart inhalers and increasing R&D activities by the key market participants propel the smart inhalers market growth in North America. Manufacturers are dedicated to enhancing smart inhalers by integrating cutting-edge technologies like sensors and cloud computing, resulting in improved iterations for widespread adoption. Personalized smart inhalers are also crafted to align with healthcare provider-prescribed medications based on patient history. Increasing research and development investments, rising support for healthcare entities, and infrastructure enhancements support the North American market forward.

The high costs associated with smart inhalers hampers the growth of the North American market. Limited awareness, insufficient smart inhaler production, and potential data misuse further hinder market expansion within the region.

This research report on the North American smart inhalers market has been segmented and sub-segmented into the following categories:

By Product Type: 

• Nebulizers
• Inhalers

By Disorder: 

• Chronic Obstructive Pulmonary Disease
• Asthma
• Others

By End-user: 

• Patients
• R&D
• Others

By Country: 

• The United States
• Canada
• Rest of North America

The North American region held the largest share of the global market in 2022. The domination of the North American region in the global market is likely to continue throughout the forecast period owing to the robust demand for advanced medical devices and increased healthcare expenditure. The U.S. smart inhalers market is anticipated to account for the largest share of the North American market in the coming years. The presence of well-established manufacturing facilities and proactive awareness campaigns promoting smart inhalers in the U.S. drive the U.S market growth. Canada is another notable regional market for smart inhalers in North America and is expected to witness a healthy CAGR in the coming years owing to the presence of key players, ongoing mergers and acquisitions, and the growing adoption of digital technology. A notable example is Canada's Breathe Suite Inc., which recently launched a U.S. FDA-cleared Metered-Dose Inhaler, benefiting nearly ten million American users.

KEY MARKET PLAYERS:

A few of the companies playing a dominant role in the North America Smart Inhalers Market profiled in this report are Vectura Group plc, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca plc, Adherium Limited, Cohero Health, LLC, Propeller Health, GlaxoSmithKline plc and OPKO Health, Inc.